echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > Danaher Named to FORTUNE's 2022 World's Most Admired Companies All-Star List (Top 50)

    Danaher Named to FORTUNE's 2022 World's Most Admired Companies All-Star List (Top 50)

    • Last Update: 2022-03-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    <>



    The "World's Most Admired Companies" list, produced by Fortune in partnership with Korn Ferry, surveyed more than 3,700 corporate executives, directors and analysts based on investment value, management and product quality, social responsibility, Nine criteria, including the ability to attract talent, rated 1,500 candidate companies in 52 industries


    The All-Star 50 list is also voted by executives, directors and analysts of these companies


    This year, the global new crown epidemic has entered its third year, economic development is struggling, and companies on the front line of the fight against the epidemic have regained attention


    Since the outbreak of the new crown epidemic, Danaher has always paid attention to and actively participated in the fight against COVID-19, launched a variety of new detection technologies and products, helped the development of new crown vaccines and related therapies, supported the acceleration of the construction of the Great Wall of Immunization, and contributed to the building of global public health capacity


    As a pioneer in the field of molecular diagnostics under the Danaher Group, Saipei continues to achieve technological breakthroughs and announced in September 2021 that its third-generation nucleic acid detection product Xpert Xpress CoV-2/Flu/RSV plus has been granted emergency use authorization by the US FDA (EUA), which adds a third gene target compared to the previous generation product to meet the challenges of future virus mutation



    At the same time, Danaher provides a wide range of technologies and solutions in the field of biological products, helping scientific researchers and biopharmaceutical companies to accelerate the development of new crown vaccines and related therapies, and is committed to supporting the accelerated launch of new therapies and rapid expansion in a short period of time.


    The Saint-Remy-sur- Avre plant in Delpharm is the first in France to produce a COVID-19 vaccine


    Despite the uncertainty in the world throughout the pandemic, the Dan family continues to excel every day - launching breakthrough technologies and products in record time, in the DBS ethos of continuous improvement, and constantly surpassing ourselves for us Our customers provide strong support, provide help and service to the communities in which we live, and together contribute more to the realization of life's potential


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.